Arthritis Care and Research : Impact Factor & More

In Response to Risk of hepatotoxicity in use of febuxostat or benzbromarone.

Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis.

TITLE: Risk of hepatotoxicity in use of febuxostat or benzbromarone.

Concerns Regarding PTX-3 Specificity and ROC Interpretation in the Study on Endothelial Biomarkers of SSc-Associated Pulmonary Hypertension.

Reply to "Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al".

Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al.

In Response to Risk of hepatotoxicity in use of febuxostat or benzbromarone.

Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis.

TITLE: Risk of hepatotoxicity in use of febuxostat or benzbromarone.

Concerns Regarding PTX-3 Specificity and ROC Interpretation in the Study on Endothelial Biomarkers of SSc-Associated Pulmonary Hypertension.

Reply to "Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al".

Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al.